Abstract: Provided are a binder composition for a secondary battery electrode, and an electrode mixture including the same, and more particularly, a binder composition for a secondary battery electrode capable of providing excellent binding strength for an active material and an electrode while having excellent latex stability, thereby improving performance of a secondary battery, and an electrode mixture including the same.

Abstract: A positive electrode active material, a method of preparing the same, and a positive electrode and lithium secondary battery including the same are disclosed herein. In some embodiments, a positive electrode active material includes a lithium transition metal oxide which contains 60 mol % or more of nickel based on a total number of moles of transition metals excluding lithium in the lithium transition metal oxide, wherein the oxide is in a form of a secondary particle which is an aggregate of primary particles, wherein the lithium transition metal oxide satisfies Equation 1: 1 ? x y ? 20 Wherein x is a minimum area of a rectangle including all pores having an area greater than 0.002 ?m2 among closed pores distributed in the secondary particle, and y is a total sum of areas of the pores having an area greater than 0.002 ?m2 among the closed pores distributed in the secondary particle.

Abstract: The present disclosure relates to an electrode binder composition for a rechargeable battery and an electrode mixture including the same. The electrode binder composition comprising an emulsified polymer particle having a core-shell structure can maintain a structural stability of the electrode even in repeated charge and discharge cycles, while having excellent properties in terms of a binding force, a mechanical property or the like, thereby improving the overall performance of the rechargeable battery.

Abstract: Provided is a smart electrochromic device. The smart electrochromic device may comprise: first and second electrodes disposed facing each other; an electrochromic layer disposed between the first and second electrodes and containing a metal oxide; and an electrolyte which is disposed between the second electrode and the electrochromic layer and which contains a mixture of a first base electrolyte containing silver (Ag), a second base electrolyte containing lithium (Li), and a solvent.

Abstract: The method of preparing a positive electrode capable of reducing the usage amount of a rinsing solution, and minimizing the surface degradation of a positive electrode active material is provided. A method of preparing a positive electrode active material includes: (A) preparing a lithium transition metal oxide; and (B) mixing the lithium transition metal oxide and a rinsing solution and performing rinsing and drying, wherein the rinsing solution includes one or more additive of LiOH, NaOH, or KOH, the additive is included in an amount of 3,000 ppm to 18,000 ppm relative to the lithium transition metal oxide in the rinsing solution, and the rinsing solution has a pH of 12 or more.

Abstract: Provided is a pharmaceutical composition including irinotecan free base. The pharmaceutical composition according to the presently claimed subject matter enables the effective oral administration of irinotecan and as such, can increase the convenience of administration of irinotecan and provide a high in vivo absorption rate, compared to conventional injections.

Abstract: Provided is a pharmaceutical composition for oral administration in the form of powder obtained by a process including: (a) preparing an emulsion including zanamivir as an active ingredient; triglyceride; acyl glycerol; a nonionic surfactant; a sugar; and water; and (b) lyophilizing the emulsion prepared in the step (a). The pharmaceutical composition according to the presently claimed subject matter can significantly increase in vivo absorption rate of zanamivir. Further, the pharmaceutical composition according to the presently claimed subject matter is in the form of powder, which not only make it easy to store and distribute but also make it possible to avoid the use of functional packaging materials for preventing changes in moisture.

Abstract: Provided is a positive electrode active material for a secondary battery which includes a composite coating layer formed on a surface of lithium composite transition metal oxide particles, wherein the composite coating layer includes a ferroelectric material and a boron-based oxide containing boron.

Abstract: A positive electrode active material contains a lithium transition metal oxide in the form of a secondary particle in which primary particles are aggregated, wherein a zirconium-containing coating film is formed on the surface of the lithium transition metal oxide secondary particle and at the interface between the primary particles present inside the secondary particle. A method of making the positive electrode active material is also provided.

Abstract: A display device according to an embodiment includes: a substrate; and a plurality of pixels, the plurality of pixels including a first pixel, a second pixel and a third pixel. Each of the plurality of pixels including a gate line extends in a first direction; a first transistor and a second transistor connected with the gate line; a pixel electrode that includes a first subpixel electrode and a second subpixel electrode; a first bridge that connects the first subpixel electrode and the first transistor; and a second bridge that connects the second subpixel electrode and the second transistor. At least one of the second pixel and the third pixel includes a light blocking pattern that overlaps at least one of the first transistor and the second transistor. The first bridge and the second bridge do not overlap or cross the light blocking pattern in a plan view.

Abstract: A display device according to an exemplary embodiment includes: a plurality of transistors disposed on a substrate; a plurality of pixel electrodes electrically connected to the plurality of transistors; a plurality of first color filters, a plurality of second color filters, and a plurality of third color filters disposed between the plurality of transistors and the plurality of pixel electrodes; and a plurality of main spacers and a plurality of sub-spacers disposed on the pixel electrode, wherein the plurality of main spacers and the plurality of sub-spacers are disposed to overlap selected portions of the plurality of first color filters in a plan view, respectively, and not to overlap the plurality of second color filters and the plurality of third color filters in a plan view.

Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.

Abstract: The present invention provides a pharmaceutical composition for oral administration, comprising (a) 4 to 40% by weight of a taxane, (b) 10 to 30% by weight of a medium chain triglyceride, (c) 30 to 70% by weight of monooleoyl glycerol, (d) 5 to 30% by weight of a surfactant, and (e) 10 to 30% by weight of polyoxyl glyceryl fatty acid ester and a process for preparing the same.

Abstract: The present invention provides a pharmaceutical composition for oral administration, consisting essentially of (a) 4 to 40% by weight of a taxane, (b) 10 to 40% by weight of polyoxyl glyceryl fatty acid ester, (c) 30 to 70% by weight of monooleoyl glycerol or 30 to 70% by weight of an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, and (d) 5 to 30% by weight of a surfactant and a process for preparing the same.

Abstract: A display device according to an embodiment includes: a substrate; and a plurality of pixels, the plurality of pixels including a first pixel, a second pixel and a third pixel. Each of the plurality of pixels including a gate line extends in a first direction; a first transistor and a second transistor connected with the gate line; a pixel electrode that includes a first subpixel electrode and a second subpixel electrode; a first bridge that connects the first subpixel electrode and the first transistor; and a second bridge that connects the second subpixel electrode and the second transistor. At least one of the second pixel and the third pixel includes a light blocking pattern that overlaps at least one of the first transistor and the second transistor. The first bridge and the second bridge do not overlap or cross the light blocking pattern in a plan view.

Abstract: A display device according to an exemplary embodiment includes: a plurality of transistors disposed on a substrate; a plurality of pixel electrodes electrically connected to the plurality of transistors; a plurality of first color filters, a plurality of second color filters, and a plurality of third color filters disposed between the plurality of transistors and the plurality of pixel electrodes; and a plurality of main spacers and a plurality of sub-spacers disposed on the pixel electrode, wherein the plurality of main spacers and the plurality of sub-spacers are disposed to overlap selected portions of the plurality of first color filters in a plan view, respectively, and not to overlap the plurality of second color filters and the plurality of third color filters in a plan view.

Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.

Abstract: The present invention relates to an oral pharmaceutical composition comprising zanamivir. Specifically, a pharmaceutical formulation comprising zanamivir as an active ingredient, and triglyceride, an acylglycerol complex and additional non-ionic surfactant, having good absorption rate in body, formulation stability, and content uniformity is provided.

Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.

Abstract: The present invention provides a pharmaceutical composition for oral administration, consisting essentially of (a) 4 to 40% by weight of a taxane, (b) 10 to 40% by weight of polyoxyl glyceryl fatty acid ester, (c) 30 to 70% by weight of monooleoyl glycerol or 30 to 70% by weight of an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, and (d) 5 to 30% by weight of a surfactant and a process for preparing the same.